All In Biotech

Drug Trial Radar · NCT07048314

Stem Cells for Erectile Dysfunction Post RALP

A Randomized Clinical Trial to Assess Safety and Efficacy of Allogeneic Adipose-derived Mesenchymal Stem Cells in Promoting the Recovery of Erectile Function Post Radical Retropubic Prostatectomy of Localized Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 7, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
The Methodist Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.

Conditions

  • Erectile Dysfunction
  • Prostate Cancer

Interventions

  • Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's officeDrug

    2.00x10⁸ HB-adMSCs IV at the doctor's office.

  • Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the ORDrug

    100 million stem cells (1.00x10⁸ HB-adMSCs) in the corpora cavernosa of the penis suspended in a 4 cc of sterile saline. 50 million stem cells (5.0x 10⁷ HB-adMSCs) along the right neurovascular bundle and 50 million cell (5.0x 10⁷ HB-adMSCs) along the left neurovascular bundle of the penis suspended in a 4 cc of sterile saline during the surgery

  • Placebo in the ORDrug

    4 cc of saline solution in the corpora cavernosa of the penis and 4 cc of saline solution along the right and left neurovascular bundles of the penis during the surgery .

  • Placebo in clinicDrug

    30 mL syringe of the product should be mixed into a 250cc bag of sodium chloride solution 0.9% for infusion. should be administered intravenously, with a dosing rate of 4-5mL/min.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in erectile function by IIEFTime frame: from baseline to 6 months post treatment
  2. Change in erectile function by Epic 26Time frame: from baseline to 6 months post treatment
  3. Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs, Immune-Related Adverse Events (irAE)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Houston Methodist

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.